Rapid immune response following melanoma treatment leads to excellent prognosis


The risk of recurrence for patients with metastatic melanomas is much smaller if their immune system starts cleaning up the tumor cells rapidly following immunotherapy, according to two studies published in Nature Medicine on February 8. “An early immune response appears to be an accurate tool to measure the efficacy and assess new therapies.”

Christian Blank, medical oncologist at the Netherlands Cancer Institute, has been involved in both Nature Magazine publications. “One of them concerns our own research. It reveals that patients who show an early immune response to immunotherapy before surgery – a treatment known as neoadjuvant immunotherapy – can rest assured that their illness won’t come back later.”

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.